Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.
Identifieur interne : 001058 ( Main/Exploration ); précédent : 001057; suivant : 001059Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.
Auteurs : Daniel C. Brennan [États-Unis] ; José M. Aguado ; Luciano Potena ; Alan G. Jardine ; Christophe Legendre ; Marcus D. S Emann ; Nicolas J. Mueller ; Pierre Merville ; Vincent Emery ; Björn NashanSource :
- Reviews in medical virology [ 1099-1654 ] ; 2013.
Descripteurs français
- KwdFr :
- Activation virale (effets des médicaments et des substances chimiques), Humains (MeSH), Immunosuppresseurs (administration et posologie), Immunosuppresseurs (effets indésirables), Immunosuppresseurs (pharmacologie), Maladies virales (induit chimiquement), Maladies virales (prévention et contrôle), Maladies virales (virologie), Transplantation (MeSH).
- MESH :
- administration et posologie : Immunosuppresseurs.
- effets des médicaments et des substances chimiques : Activation virale.
- effets indésirables : Immunosuppresseurs.
- induit chimiquement : Maladies virales.
- pharmacologie : Immunosuppresseurs.
- prévention et contrôle : Maladies virales.
- virologie : Maladies virales.
- Humains, Transplantation.
English descriptors
- KwdEn :
- Humans (MeSH), Immunosuppressive Agents (administration & dosage), Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (pharmacology), Transplantation (MeSH), Virus Activation (drug effects), Virus Diseases (chemically induced), Virus Diseases (prevention & control), Virus Diseases (virology).
- MESH :
- chemical , administration & dosage : Immunosuppressive Agents.
- chemical , adverse effects : Immunosuppressive Agents.
- chemical , pharmacology : Immunosuppressive Agents.
- chemically induced : Virus Diseases.
- drug effects : Virus Activation.
- prevention & control : Virus Diseases.
- virology : Virus Diseases.
- Humans, Transplantation.
Abstract
Recent evidence suggesting a potential anti-CMV effect of mTORis is of great interest to the transplant community. However, the concept of an immunosuppressant with antiviral properties is not new, with many accounts of the antiviral properties of several agents over the years. Despite these reports, to date, there has been little effort to collate the evidence into a fuller picture. This manuscript was developed to gather the evidence of antiviral activity of the agents that comprise a typical immunosuppressive regimen against viruses that commonly reactivate following transplant (HHV1 and 2, VZV, EBV, CMV and HHV6, 7, and 8, HCV, HBV, BKV, HIV, HPV, and parvovirus). Appropriate immunosuppressive regimens posttransplant that avoid acute rejection while reducing risk of viral reactivation are also reviewed. The existing literature was disparate in nature, although indicating a possible stimulatory effect of tacrolimus on BKV, potentiation of viral reactivation by steroids, and a potential advantage of mammalian target of rapamycin (mTOR) inhibition in several viral infections, including BKV, HPV, and several herpesviruses.
DOI: 10.1002/rmv.1733
PubMed: 23165654
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.</title><author><name sortKey="Brennan, Daniel C" sort="Brennan, Daniel C" uniqKey="Brennan D" first="Daniel C" last="Brennan">Daniel C. Brennan</name><affiliation wicri:level="4"><nlm:affiliation>Washington University in St Louis, St Louis, MO 63110, USA. brennan@wudosis.wustl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Washington University in St Louis, St Louis, MO 63110</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">Université Washington de Saint-Louis</orgName></affiliation></author><author><name sortKey="Aguado, Jose M" sort="Aguado, Jose M" uniqKey="Aguado J" first="José M" last="Aguado">José M. Aguado</name></author><author><name sortKey="Potena, Luciano" sort="Potena, Luciano" uniqKey="Potena L" first="Luciano" last="Potena">Luciano Potena</name></author><author><name sortKey="Jardine, Alan G" sort="Jardine, Alan G" uniqKey="Jardine A" first="Alan G" last="Jardine">Alan G. Jardine</name></author><author><name sortKey="Legendre, Christophe" sort="Legendre, Christophe" uniqKey="Legendre C" first="Christophe" last="Legendre">Christophe Legendre</name></author><author><name sortKey="S Emann, Marcus D" sort="S Emann, Marcus D" uniqKey="S Emann M" first="Marcus D" last="S Emann">Marcus D. S Emann</name></author><author><name sortKey="Mueller, Nicolas J" sort="Mueller, Nicolas J" uniqKey="Mueller N" first="Nicolas J" last="Mueller">Nicolas J. Mueller</name></author><author><name sortKey="Merville, Pierre" sort="Merville, Pierre" uniqKey="Merville P" first="Pierre" last="Merville">Pierre Merville</name></author><author><name sortKey="Emery, Vincent" sort="Emery, Vincent" uniqKey="Emery V" first="Vincent" last="Emery">Vincent Emery</name></author><author><name sortKey="Nashan, Bjorn" sort="Nashan, Bjorn" uniqKey="Nashan B" first="Björn" last="Nashan">Björn Nashan</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23165654</idno><idno type="pmid">23165654</idno><idno type="doi">10.1002/rmv.1733</idno><idno type="wicri:Area/Main/Corpus">001087</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001087</idno><idno type="wicri:Area/Main/Curation">001087</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">001087</idno><idno type="wicri:Area/Main/Exploration">001087</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.</title><author><name sortKey="Brennan, Daniel C" sort="Brennan, Daniel C" uniqKey="Brennan D" first="Daniel C" last="Brennan">Daniel C. Brennan</name><affiliation wicri:level="4"><nlm:affiliation>Washington University in St Louis, St Louis, MO 63110, USA. brennan@wudosis.wustl.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Washington University in St Louis, St Louis, MO 63110</wicri:regionArea><placeName><region type="state">Missouri (État)</region><settlement type="city">Saint-Louis (Missouri)</settlement></placeName><orgName type="university">Université Washington de Saint-Louis</orgName></affiliation></author><author><name sortKey="Aguado, Jose M" sort="Aguado, Jose M" uniqKey="Aguado J" first="José M" last="Aguado">José M. Aguado</name></author><author><name sortKey="Potena, Luciano" sort="Potena, Luciano" uniqKey="Potena L" first="Luciano" last="Potena">Luciano Potena</name></author><author><name sortKey="Jardine, Alan G" sort="Jardine, Alan G" uniqKey="Jardine A" first="Alan G" last="Jardine">Alan G. Jardine</name></author><author><name sortKey="Legendre, Christophe" sort="Legendre, Christophe" uniqKey="Legendre C" first="Christophe" last="Legendre">Christophe Legendre</name></author><author><name sortKey="S Emann, Marcus D" sort="S Emann, Marcus D" uniqKey="S Emann M" first="Marcus D" last="S Emann">Marcus D. S Emann</name></author><author><name sortKey="Mueller, Nicolas J" sort="Mueller, Nicolas J" uniqKey="Mueller N" first="Nicolas J" last="Mueller">Nicolas J. Mueller</name></author><author><name sortKey="Merville, Pierre" sort="Merville, Pierre" uniqKey="Merville P" first="Pierre" last="Merville">Pierre Merville</name></author><author><name sortKey="Emery, Vincent" sort="Emery, Vincent" uniqKey="Emery V" first="Vincent" last="Emery">Vincent Emery</name></author><author><name sortKey="Nashan, Bjorn" sort="Nashan, Bjorn" uniqKey="Nashan B" first="Björn" last="Nashan">Björn Nashan</name></author></analytic><series><title level="j">Reviews in medical virology</title><idno type="eISSN">1099-1654</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Humans (MeSH)</term><term>Immunosuppressive Agents (administration & dosage)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (pharmacology)</term><term>Transplantation (MeSH)</term><term>Virus Activation (drug effects)</term><term>Virus Diseases (chemically induced)</term><term>Virus Diseases (prevention & control)</term><term>Virus Diseases (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Activation virale (effets des médicaments et des substances chimiques)</term><term>Humains (MeSH)</term><term>Immunosuppresseurs (administration et posologie)</term><term>Immunosuppresseurs (effets indésirables)</term><term>Immunosuppresseurs (pharmacologie)</term><term>Maladies virales (induit chimiquement)</term><term>Maladies virales (prévention et contrôle)</term><term>Maladies virales (virologie)</term><term>Transplantation (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Immunosuppresseurs</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Virus Activation</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Activation virale</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Immunosuppresseurs</term></keywords><keywords scheme="MESH" qualifier="induit chimiquement" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Immunosuppresseurs</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Maladies virales</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Virus Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Transplantation</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Transplantation</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Recent evidence suggesting a potential anti-CMV effect of mTORis is of great interest to the transplant community. However, the concept of an immunosuppressant with antiviral properties is not new, with many accounts of the antiviral properties of several agents over the years. Despite these reports, to date, there has been little effort to collate the evidence into a fuller picture. This manuscript was developed to gather the evidence of antiviral activity of the agents that comprise a typical immunosuppressive regimen against viruses that commonly reactivate following transplant (HHV1 and 2, VZV, EBV, CMV and HHV6, 7, and 8, HCV, HBV, BKV, HIV, HPV, and parvovirus). Appropriate immunosuppressive regimens posttransplant that avoid acute rejection while reducing risk of viral reactivation are also reviewed. The existing literature was disparate in nature, although indicating a possible stimulatory effect of tacrolimus on BKV, potentiation of viral reactivation by steroids, and a potential advantage of mammalian target of rapamycin (mTOR) inhibition in several viral infections, including BKV, HPV, and several herpesviruses.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23165654</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2013</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1654</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Reviews in medical virology</Title><ISOAbbreviation>Rev Med Virol</ISOAbbreviation></Journal><ArticleTitle>Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.</ArticleTitle><Pagination><MedlinePgn>97-125</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/rmv.1733</ELocationID><Abstract><AbstractText>Recent evidence suggesting a potential anti-CMV effect of mTORis is of great interest to the transplant community. However, the concept of an immunosuppressant with antiviral properties is not new, with many accounts of the antiviral properties of several agents over the years. Despite these reports, to date, there has been little effort to collate the evidence into a fuller picture. This manuscript was developed to gather the evidence of antiviral activity of the agents that comprise a typical immunosuppressive regimen against viruses that commonly reactivate following transplant (HHV1 and 2, VZV, EBV, CMV and HHV6, 7, and 8, HCV, HBV, BKV, HIV, HPV, and parvovirus). Appropriate immunosuppressive regimens posttransplant that avoid acute rejection while reducing risk of viral reactivation are also reviewed. The existing literature was disparate in nature, although indicating a possible stimulatory effect of tacrolimus on BKV, potentiation of viral reactivation by steroids, and a potential advantage of mammalian target of rapamycin (mTOR) inhibition in several viral infections, including BKV, HPV, and several herpesviruses.</AbstractText><CopyrightInformation>Copyright © 2012 John Wiley & Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brennan</LastName><ForeName>Daniel C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Washington University in St Louis, St Louis, MO 63110, USA. brennan@wudosis.wustl.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aguado</LastName><ForeName>José M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Potena</LastName><ForeName>Luciano</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Jardine</LastName><ForeName>Alan G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Legendre</LastName><ForeName>Christophe</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Säemann</LastName><ForeName>Marcus D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Nicolas J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>Merville</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Emery</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Nashan</LastName><ForeName>Björn</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Rev Med Virol</MedlineTA><NlmUniqueID>9112448</NlmUniqueID><ISSNLinking>1052-9276</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014180" MajorTopicYN="N">Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014775" MajorTopicYN="N">Virus Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014777" MajorTopicYN="N">Virus Diseases</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>05</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>09</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>11</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23165654</ArticleId><ArticleId IdType="doi">10.1002/rmv.1733</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Missouri (État)</li></region><settlement><li>Saint-Louis (Missouri)</li></settlement><orgName><li>Université Washington de Saint-Louis</li></orgName></list><tree><noCountry><name sortKey="Aguado, Jose M" sort="Aguado, Jose M" uniqKey="Aguado J" first="José M" last="Aguado">José M. Aguado</name><name sortKey="Emery, Vincent" sort="Emery, Vincent" uniqKey="Emery V" first="Vincent" last="Emery">Vincent Emery</name><name sortKey="Jardine, Alan G" sort="Jardine, Alan G" uniqKey="Jardine A" first="Alan G" last="Jardine">Alan G. Jardine</name><name sortKey="Legendre, Christophe" sort="Legendre, Christophe" uniqKey="Legendre C" first="Christophe" last="Legendre">Christophe Legendre</name><name sortKey="Merville, Pierre" sort="Merville, Pierre" uniqKey="Merville P" first="Pierre" last="Merville">Pierre Merville</name><name sortKey="Mueller, Nicolas J" sort="Mueller, Nicolas J" uniqKey="Mueller N" first="Nicolas J" last="Mueller">Nicolas J. Mueller</name><name sortKey="Nashan, Bjorn" sort="Nashan, Bjorn" uniqKey="Nashan B" first="Björn" last="Nashan">Björn Nashan</name><name sortKey="Potena, Luciano" sort="Potena, Luciano" uniqKey="Potena L" first="Luciano" last="Potena">Luciano Potena</name><name sortKey="S Emann, Marcus D" sort="S Emann, Marcus D" uniqKey="S Emann M" first="Marcus D" last="S Emann">Marcus D. S Emann</name></noCountry><country name="États-Unis"><region name="Missouri (État)"><name sortKey="Brennan, Daniel C" sort="Brennan, Daniel C" uniqKey="Brennan D" first="Daniel C" last="Brennan">Daniel C. Brennan</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001058 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001058 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23165654
|texte= Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23165654" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |